4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Q4 2020 13F Holders as of 12/31/2020

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 45.2M
Number of holders: 50
Total 13F shares, excl. options: 13M
Shares change: +12.4M
Total reported value, excl. options: $536M
Value change: +$512M
Number of buys: 47
Price: $41.45

Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q4 2020

50 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2020.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13M shares of 45.2M outstanding shares and own 28.78% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (3.94M shares), BVF INC/IL (1.11M shares), ArrowMark Colorado Holdings LLC (1.06M shares), JANUS HENDERSON GROUP PLC (1.02M shares), Casdin Capital, LLC (781K shares), SB Management Ltd (718K shares), PERCEPTIVE ADVISORS LLC (600K shares), ALKEON CAPITAL MANAGEMENT LLC (402K shares), Octagon Capital Advisors LP (378K shares), and MILLENNIUM MANAGEMENT LLC (344K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.